ARS Pharmaceuticals, Inc.'s stock soared 25% on strong earnings. Learn about neffy's market potential, risks, and future ...

Learn more about whether Globus Medical, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor ...

When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off ...

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

People are worried that they’ve become immune to Botox — not that you’d be able to see it on their face. The wildly popular ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York ...

Ireland’s Mallinckrodt will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion. The companies said ...

The new entity will be listed on the New York Stock Exchange and is expected to generate pro forma revenue of $3.6 billion in ...

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...

CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735.CordenPharma provides large-scale ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...